Company intelligence / Profile preview

Epredia

Portsmouth, New Hampshire, United Statesepredia.com ↗

Ownership: Private
Employees: ~850
Development stage: Commercial

Overview

Epredia develops and commercializes precision cancer diagnostic products and solutions for pathology laboratories worldwide. Their portfolio includes tissue processors, microtome blades, cassettes, staining systems, digital pathology platforms such as the FDA-cleared E1000 Dx Digital Pathology Solution. The company’s technologies are widely used in clinical practice to improve workflow efficiency and diagnostic accuracy in cancer care. No clinical trial results as the company does not develop therapeutics.

Therapeutic areas: Oncology
Modalities: Device
Industry: Pathology

Beyond the preview

Go deeper on Epredia.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Epredia.

Explore the full profile